Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)

Conclusions: Absent or diminished expression of IGF-1R after neoadjuvant chemotherapy was associated with a better pathological response. Additionally, we found a SNP (rs2016347) in IGF1R as a potential predictive marker for chemotherapy efficacy in BC patients treated with TAC.Trial registrationClinicalTrials.gov NCT01099436. Registered April 6, 2010.

http://breast-cancer-research.com/content/18/1/3

Source: Breast Cancer Research - January 6, 2016 Category: Cancer & Oncology Authors: Stefanie de GrootAyoub CharehbiliHanneke van LaarhovenAntien MooyaartN. Dekker-EnsinkSaskia van de VenLaura JanssenJesse SwenVincent SmitJoan HeijnsLonneke KesselsTahar van der StraatenStefan BöhringerHans GelderblomJacobus van der HoevenHenk-Jan Guchela Source Type: research

Insulin-like growth factor 1 receptor expression and IGF1R 3129G&#8201;&gt;&#8201;T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)

Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)